BRCA1 and triple-negative breast carcinoma: Subsequently, Quereda V. et al. showed that SR-4835, a recently developed specific inhibitor of CDK12/13, sensitized triple-negative breast cancer cells to PARP inhibitors and DNA-damaging chemotherapeutic drugs by reducing the expressions of homologous recombination genes, specifically BRCA1 and -2 [17].